NeuroVive completes 10 percent acquisition of Isomerase Therapeutics
Regulatory News:
NeuroVive Pharmaceutical AB (STO:NVP), the mitochondrial medicine company, today announces that the second step in the
previously announced partial acquisition of the British drug discovery and development company Isomerase Therapeutics Ltd
(Isomerase), has been completed. NeuroVive now holds approximately 10 percent of the shares in Isomerase. The overall aim with the
acquisition is to strengthen the existing partnership and accelerate NeuroVive’s research and development (R&D) program.
The now completed acquisition includes approximately 5% further of the shares in Isomerase through a 550 000 GBP cash
payment. The first step in the acquisition was executed January 14, 2016 (http://publish.ne.cision.com/Release/ViewReleaseHtml/91E0B436350950EF) when NeuroVive acquired approximately 5
percent of the shares in Isomerase by payment in own shares.
NeuroVive is committed to the discovery and development of highly targeted drug candidates that can improve and support
mitochondrial function in disease areas with a high medical need. The completed holding in Isomerase is in line with NeuroVive's
business strategy of value-adding partnerships with mitochondrial research and development players and commercial partners
globally. The joint teams at NeuroVive and Isomerase are currently working on the research project NVP015 (complex I dysfunction)
and several other discovery programs which all are progressing well.
“We are very happy with how our collaboration with Isomerase has evolved throughout the years. We have together with Isomerase
been able to efficiently advance our prioritized research program NVP015 and generate new compounds that currently are evaluated in
experimental models”, commented Erik Kinnman, CEO NeuroVive.
About Isomerase
Isomerase Therapeutics (www.isomerase.co.uk) is an agile drug discovery and development company based in Cambridge, UK and is a leader
in the discovery and development of compounds that target molecules such as cyclophilins. The Company is led by an experienced team
with a successful track record in the discovery, development and commercialization of drugs by applying a combination of
biosynthetic engineering and synthetic chemistry. The team at Isomerase is actively involved in the pharmacology, chemistry and
manufacturing for several of NeuroVive’s projects.
About NeuroVive
NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a company committed to the discovery and
development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic
need. NeuroVive's business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial
partners across the globe.
NeuroVive's portfolio consists of two clinical projects, one in acute kidney injury (CicloMulsion®) and one in traumatic brain
injury (NeuroSTAT®). The candidate drug NeuroSTAT has orphan drug designation in Europe and in the US for treatment of moderate to
severe traumatic brain injury and is currently being evaluated in the CHIC study. CicloMulsion is being evaluated in an on-going
study, CiPRICS, in acute kidney injury during major surgery. Furthermore, the R&D portfolio consists of two late stage
discovery programs and one compound in preclinical development.
NeuroVive is listed on Nasdaq Stockholm, Sweden, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC
Markets Group Inc market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTCQX Best Market.
NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) Fax: +46 (0)46
888 83 48 www.neurovive.com
This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market
Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 1:30
p.m. CEST on August 15, 2016.
This information was brought to you by Cision http://news.cision.com
NeuroVive
Cecilia Hofvander
Tel: +46 (0)46 275 62 21
ir@neurovive.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160815005506/en/